LIPAC Oncology Announces Acceptance of an Abstract for Presentation at the American Urological Association Annual Meeting in May 2020
(San Francisco, Calif.) January 12, 2020 - LIPAC Oncology LLC today announced the acceptance of an abstract for presentation at the American Urological Association (AUA) annual meeting to be held May 15-18, 2020 in Washington, D.C. The poster, “Phase 1 Outcomes of a Novel Third Generation Liposomal Paclitaxel Formulation (TSD-001) in Low-Intermediate Risk Non-Muscle Invasive Bladder Cancer (NMIBC) Patients,” provides an important update on the clinical development of LiPax™ (TSD-001), a Proliposomal Intracavity Paclitaxel (PLIP) formulation in development for intravesical administration in the treatment of NMIBC.
“Our presence at AUA illustrates LIPAC’s commitment to develop proven cancer drugs into more effective treatments for intracavity cancers,” said Michael Oefelein, Chief Medical Officer of LIPAC. “New treatment options and more effective delivery systems could help improve both clinical outcomes and quality of life for people living with cancer.”
In October 2019, LIPAC announced the completion of the Phase 1 clinical study and progress in a Phase 2A marker lesion clinical study to establish efficacy responder rates. Phase 1 study results showed escalating doses of LiPax to be well tolerated with no dose limiting toxicity and no irritative voiding (cystitis) symptoms. No systemic exposure or toxicity was observed, even with high concentrations of LiPax being delivered topically to the bladder wall. Phase 1 results also indicated preliminary efficacy with no evidence of bladder cancer recurrences observed up to 18 months after dosing. Adverse events were minor.
About LIPAC Oncology LLC
LIPAC Oncology is a pharmaceutical company utilizing the proprietary proliposomal delivery system to enhance and reformulate proven cancer drugs into more effective treatments. The company was created in 2016 as a subsidiary of TesoRx Pharma LLC, a pharmaceutical company which has leveraged the platform technology to create therapeutic candidates for other indications. For more information, visit lipaconcology.com.
About TesoRx Pharma LLC
TesoRx Pharma LLC is focused on rapidly developing and commercializing pharmaceutical products in rare and specialty markets with limited treatment options and high unmet needs. Its growing pipeline includes assets in urology, oncology and rare diseases that have been formulated with TesoRx’s proprietary proliposomal delivery technology. The company was founded in 2010 through a collaboration with Western University of Health Sciences that includes joint R&D efforts at the TesoRx Centre of Excellence in Pomona, California. For more information, visit tesorx.com.
###